635731-99-6

Basic information

• Product Name: 3-Pyridinecarbonitrile, 2-bromo-4-[(4-methoxyphenyl)methoxy]-
• CAS NO: 635731-99-6
• Molecular Formula: C14H11BrN2O2
• Molecular Weight: 319.158
• Mol File: 635731-99-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarbonitrile, 2-bromo-4-[(4-methoxyphenyl)methoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonitrile, 2-bromo-4-[(4-methoxyphenyl)methoxy]-(635731-99-6)
• EPA Substance Registry System: 3-Pyridinecarbonitrile, 2-bromo-4-[(4-methoxyphenyl)methoxy]-(635731-99-6)

Safety Data

• Hazardous Substances Data: 635731-99-6(Hazardous Substances Data)

Upstream product

• 98645-43-3 2-chloro-3-cyano-4-methoxypyridine 
• 635731-97-4 2-bromo-3-cyano-4-hydroxypyridine 
• 824-94-2 p-methoxybenzyl chloride 
• 869802-74-4 2-chloro-3-cyano-4-hydroxypyridine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 

Downstream Products

• 635731-04-3 3-amino-4-(4-nitrophenylamino)thieno[2,3-b]pyridine-2-carboxylic acid amide 
• 635731-06-5 3-amino-4-(4-benzylpiperazin-1-yl)thieno[2,3-b]pyridine-2-carboxylic acid amide 
• 147992-83-4 3-amino-4-phenylaminothieno[2,3-b]pyridine-2-carboxylic acid amide 
• 869802-28-8 5-amino-4-(4'-methoxybenzyloxy)thieno[8,9-b]pyridine-6-carboxylic acid methyl ester 

Relevant articles and documents

ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF

The present invention discloses compounds of general formula (I) wherein X1-X4 and R1-R3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.

SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES

Disclosed are compounds of formula (I), wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.